Business
J&J bags Firefly Bio's degrader antibody conjugate platform for USD 1b
Johnson & Johnson (NYSE: JNJ) has agreed to acquire Firefly Bio, Inc. for USD 1 billion in cash, adding the company's proprietary Firelink™ degrader...
Soligenix seeks CEPI backing for Ebola vaccine development
Princeton, New Jersey-based Soligenix, Inc. (Nasdaq: SNGX) has announced that it is applying to the Coalition for Epidemic Preparedness Innovations (CEPI)...
GSK makes USD 10.6b move for Nuvalent to enter lung cancer with ROS1 and ALK inhibitors
GSK has agreed to acquire Nuvalent, Inc. (Nasdaq: NUVL) for USD 10.6 billion, gaining two late-stage kinase inhibitors — zidesamtinib (NVL-520) and...
Incyte to acquire Vega Therapeutics for USD 2.0b targeting mAb for VWD
Incyte (Nasdaq: INCY) has agreed to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, for USD 1.25 billion upfront, with...
GSK partners with Engitix on liver fibrosis regression using human extracellular matrix platform, up to USD 59.4m upfront
GSK has entered a research collaboration and option agreement with UK-based Engitix Ltd. to identify and validate novel therapeutic targets for liver...
Sanofi expands Owkin partnership for purpose-built AI agents
Sanofi has signed a multi-year collaboration agreement with Owkin, the Franco-American agentic AI company, to co-develop bespoke AI agents deployed through...
Shilpa Medicare takes equity stake in Gate2Brain for preclinical brain cancer peptide conjugate
India-based Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Spain-based Gate2Brain, S.L. to advance G2B-002, a...
GNI Group acquires Ayumi Pharmaceutical from Blackstone for USD 280m
Japan-based GNI Group Co., Ltd. (TSE: 2160) has agreed to acquire 100% of the shares of Ayumi Pharmaceutical Holdings Co., Ltd. from shareholders led by...
Everest Medicines gains exclusive Greater China rights to Corxel's presbyopia eye drop
Everest Medicines (HKEX: 01952) has secured exclusive rights to develop and commercialize LNZ100, a once-daily aceclidine eye drop for presbyopia, across...
Karo expands license with Moberg Pharma to include China e-commerce
Karo Healthcare has extended its license agreement with Stockholm-based Moberg Pharma (Nasdaq Stockholm: MOB) to cover China, adding the world's most...
Roche commits USD 700m upfront to co-develop Nurix BTK degrader bexobrutideg across oncology and immunology
Roche commits USD 700 million upfront — one of the largest deals in the targeted protein degradation space — to co-develop and co-commercialize...
Gilead, Lakefront complete USD 2.175b acquisition of Ouro Med targeting BCMAxCD3 BsAb gamgeramig
Gilead Sciences (Nasdaq: GILD) and Belgium-based Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT) have completed the joint acquisition of Ouro...
Stipple Bio partners with Lonza on multi-target ADC platform for precision oncology therapies
Cambridge, Massachusetts-based Stipple Bio, Inc. has entered a multi-target license agreement with Switzerland-based Lonza (SIX: LONN) to access the CDMO's...
Made Scientific and Pluristyx launch integrated iPSC development and manufacturing partnership
Princeton, New Jersey-based Made Scientific, Inc., a cell therapy contract development and manufacturing organization backed by South Korea's GC...
Pfizer signs up to access Chai Discovery's generative AI platform for next-gen antibody design
Pfizer (NYSE: PFE) has licensed San Francisco-based Chai Discovery's generative AI platform — including early access to Chai-3, a previously undisclosed...
The AllSci Brief
Systematic R&D and deal news. Daily.